When:
Monday, November 6, 2023 - 12:00am
A multinational pharmaceutical company is seeking novel biology or therapeutic compounds for the treatment of Immunology & Inflammation (I&I) diseases, such as asthma and chronic obstructive pulmonary disorder (COPD). The team is particularly interested in approaches that have a novel mechanism of action for these diseases with no therapeutics currently in the clinic acting on the same target, however differentiated modalities for known targets are also of interest (e.g. small molecule or oral peptides for validated targets with biologics).